Developer docs
API playgroundTry for free, no card

Search company profiles

Mobility Health

Full company profile

uuid002b1ti

Namestring
Mobility Health
Legal namestring
Mira Precision Health
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Mobility Health, doing business as Mira Precision Health, is a CLIA-certified clinical laboratory founded in 2021 and headquartered in Mason, Ohio. The company operates a pharmacogenomic (PGx) testing platform built around two branded products: Mira Comprehensive PGx, a broad panel covering 85+ commonly prescribed medications across 12 therapeutic areas (mental health, cardiology, pain management, oncology, autoimmune disorders, organ transplants, infection/immunity), and ToxNav Advantage, an oncology-focused test covering all AMP Tier 1 and Tier 2 DPYD variants plus UGT1A1 testing for irinotecan dosing, with results aligned to FDA labeling and NCCN Clinical Practice Guidelines. Testing is supported by a clinical decision support software layer, a proprietary laboratory platform designed to handle low-quality DNA samples, and a web-based provider portal for ordering and results retrieval. Scientific underpinning for the oncology franchise is provided through a partnership with Oxford Cancer Biomarkers.

The company sells primarily to community clinics, healthcare providers, and long-term care facilities through a direct sales motion, with testing delivered via the provider portal and reimbursed under Medicare. All services feature a stated 48-hour turnaround time. Beyond PGx, the lab also offers in-vitro diagnostics, custom molecular assay development and validation for clinical and research partners, and serological testing for infectious disease detection. The company maintains CLIA certification (CLIA# 36D2194362), HITRUST certification, HIPAA/HITECH compliance, GINA adherence, and WBENC women-owned business certification. There are no disclosed funding rounds, ownership details, revenue figures, or named enterprise customers in the available data.

Short descriptiontext

Mobility Health (Mira Precision Health) is a CLIA-certified clinical laboratory offering pharmacogenomic testing across 85+ medications and 12 therapeutic areas for community clinics, healthcare providers, and long-term care facilities, with 48-hour turnaround and Medicare reimbursement.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMason, United States
HQ citystring
Mason
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmacogenomic testing, precision medicine diagnostics, clinical laboratory services, oncology genetic testing, DNA-guided prescribing
Industry1 code
PRIMARYHLAAANAB
Pharmacogenomics (PGx) Decision Support
NAICS code1 code
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Pharmacogenomic Testing Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medicare-Covered PGx Testing
TypeProfessional Services
Description

Laboratory testing services for pharmacogenomic testing that is covered by Medicare, indicating reimbursement through government healthcare programs. The company provides testing services to healthcare providers who order tests for their patients.

miraprecision.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Pricing details1 tier
1Medicare-covered testing for eligible patients
ModelOtherBilling cadencePay-as-you-go
Notes

Mira Precision Health's pharmacogenomic testing is Medicare-covered, helping reduce patient costs. Specific pricing tiers or rates are not publicly disclosed.

miraprecision.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1ToxNav Advantage
Description

Oncology pharmacogenomic testing for DPYD and UGT1A1 variants to help reduce chemotoxicity from fluoropyrimidines and irinotecan.

miraprecision.com
+1 more record
Core offering1 text field

Mobility Health (operating as Mira Precision Health) is a CLIA-certified clinical laboratory providing pharmacogenomic (PGx) testing services to healthcare providers. Its two flagship offerings are Mira Comprehensive PGx, covering 85+ medications across 12 therapeutic areas, and ToxNav Advantage, an oncology-focused test covering all AMP Tier 1 and Tier 2 DPYD variants plus UGT1A1 testing to assess chemotherapy toxicity risk. Tests are delivered with an industry-best 48-hour turnaround time through a secure provider portal with EMR integration.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Industry-best 48-hour turnaround time for pharmacogenomic test results
+3 more records
Product overview1 text field

Mira Precision Health (Mobility Health) offers a pharmacogenomic testing platform consisting of two main branded test products: Mira Comprehensive PGx for general medication guidance across 85+ medications in 12 therapeutic areas, and ToxNav Advantage for specialized oncology pharmacogenomic testing to reduce chemotherapy toxicity. These products are supported by proprietary clinical decision support software, delivered through a provider portal, and backed by CLIA-certified in-vitro diagnostic laboratory services. All products feature a 48-hour turnaround time.

Product and service4 records
1Mira Comprehensive PGx
CategoryPharmacogenomic Testing
Description

Comprehensive pharmacogenomic test providing medication guidance for 85+ commonly prescribed medications across 12 therapeutic areas including mental health, cardiology, pain management, infection/immunity, oncology, autoimmune disorders, and organ transplant care. Delivered with a 48-hour turnaround time to healthcare providers for use in clinical decision-making.

2ToxNav Advantage
CategoryOncology Pharmacogenomic Testing
Description

Oncology-focused pharmacogenomic test covering all AMP Tier 1 and Tier 2 DPYD variants for fluoropyrimidine toxicity risk plus UGT1A1 testing for irinotecan dosing guidance. Results are aligned with FDA labeling and NCCN Clinical Practice Guidelines in Oncology. Powered by Oxford Cancer Biomarkers science, with a 48-hour turnaround time.

3In-Vitro Diagnostics Laboratory Services
CategoryClinical Laboratory Services
Description

CLIA-certified high-complexity clinical laboratory services specializing in advanced nucleic acid analysis, assay development and validation, and high-throughput molecular testing. Offered to laboratories, pharmaceutical partners, and clinical or R&D teams seeking custom diagnostic programs and precision-medicine initiatives.

4Serological Testing
CategoryDiagnostic Laboratory Services
Description

In-vitro diagnostic services for infectious disease detection and immunity assessment, provided through the company's CLIA-certified laboratory. Targeted at healthcare providers needing serological testing support.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Oxford Cancer Biomarkers
Strategic tierCoreTypeTechnology or Integration
Description

Oxford Cancer Biomarkers provides the scientific foundation powering Mira Precision Health's ToxNav Advantage oncology testing platform. The partnership enables DPYD and UGT1A1 testing with results aligned to FDA labeling and NCCN Guidelines.

miraprecision.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Tempus Labs
TypeBroad incumbent
Description

Tempus is a large precision medicine platform combining molecular profiling, data, and AI. It is a broad incumbent covering oncology molecular diagnostics and PGx-adjacent testing, competing for the same provider and oncology accounts.

TypeBroad incumbent
Description

Caris provides molecular profiling and AI-driven precision medicine, notably in oncology. It is a broad incumbent that overlaps with Mira's oncology pharmacogenomic and molecular diagnostic ambitions at a much larger scale.

TypeDirect peer
Description

OneOme is a pharmacogenomic decision support platform offering RightMed, a multi-gene PGx test used by providers for medication guidance across similar therapeutic areas. It directly competes with Mira Comprehensive PGx in clinical pharmacology testing for healthcare providers.

TypeDirect peer
Description

Genomind is a PGx testing company focused on mental health medication management, with its Genecept Assay covering psychotropic-relevant genes. It is a direct competitor in the provider-ordered PGx testing category, particularly overlapping with Mira's mental health therapeutic area.

TypeBroad incumbent
Description

GeneDx is an established clinical genetics and rare disease diagnostics company with broad hereditary and pharmacogenomic offerings. As a broad incumbent with national infrastructure, it competes for similar provider accounts in clinical genetic testing.

TypeBroad incumbent
Description

Castle Biosciences is a molecular diagnostics company specializing in dermatologic and oncology tests. It is a broad incumbent in specialty molecular diagnostics, relevant as a competitor for provider-directed, oncology-related testing.

TypeDirect peer
Description

RxGenomix provides PGx interpretation and clinical decision support for pharmacists and providers. It directly competes in the same medication-management-PGx category as Mira Precision Health.

TypeBroad incumbent
Description

Myriad Genetics acquired Assurex Health to offer GeneSight, a leading mental-health PGx test. As a large, publicly traded genetics company, it is a broad incumbent that overlaps with Mira's PGx offerings but operates across a much wider diagnostic portfolio.

TypeBroad incumbent
Description

PathGroup is a large reference laboratory offering molecular and clinical testing across the Southeast and broader US. It is a broad incumbent in clinical laboratory services with overlapping capabilities to Mira's CLIA-certified diagnostic offerings.

TypeDirect peer
Description

Coriell Life Sciences offers pharmacogenomic testing and clinical interpretation services for healthcare organizations. It is a direct peer in PGx decision support with a similarly provider-focused go-to-market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mobility Health

Pharmacogenomic Testing Servicesmobilityhealthlab.com

Mobility Health (Mira Precision Health) is a CLIA-certified clinical laboratory offering pharmacogenomic testing across 85+ medications and 12 therapeutic areas for community clinics, healthcare providers, and long-term care facilities, with 48-hour turnaround and Medicare reimbursement.

What Mobility Health does

Mobility Health, doing business as Mira Precision Health, is a CLIA-certified clinical laboratory founded in 2021 and headquartered in Mason, Ohio. The company operates a pharmacogenomic (PGx) testing platform built around two branded products: Mira Comprehensive PGx, a broad panel covering 85+ commonly prescribed medications across 12 therapeutic areas (mental health, cardiology, pain management, oncology, autoimmune disorders, organ transplants, infection/immunity), and ToxNav Advantage, an oncology-focused test covering all AMP Tier 1 and Tier 2 DPYD variants plus UGT1A1 testing for irinotecan dosing, with results aligned to FDA labeling and NCCN Clinical Practice Guidelines. Testing is supported by a clinical decision support software layer, a proprietary laboratory platform designed to handle low-quality DNA samples, and a web-based provider portal for ordering and results retrieval. Scientific underpinning for the oncology franchise is provided through a partnership with Oxford Cancer Biomarkers.

The company sells primarily to community clinics, healthcare providers, and long-term care facilities through a direct sales motion, with testing delivered via the provider portal and reimbursed under Medicare. All services feature a stated 48-hour turnaround time. Beyond PGx, the lab also offers in-vitro diagnostics, custom molecular assay development and validation for clinical and research partners, and serological testing for infectious disease detection. The company maintains CLIA certification (CLIA# 36D2194362), HITRUST certification, HIPAA/HITECH compliance, GINA adherence, and WBENC women-owned business certification. There are no disclosed funding rounds, ownership details, revenue figures, or named enterprise customers in the available data.

Mobility Health firmographics

Firmographics
Name
Mobility Health
Legal name
Mira Precision Health
Website
https://mobilityhealthlab.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Mobility Health (Mira Precision Health) is a CLIA-certified clinical laboratory offering pharmacogenomic testing across 85+ medications and 12 therapeutic areas for community clinics, healthcare providers, and long-term care facilities, with 48-hour turnaround and Medicare reimbursement.
Ownership category
akta.pro rank

Mobility Health industry classification

Industry
Product category
Pharmacogenomic Testing Services
NAICS
Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAANAB
Pharmacogenomics (PGx) Decision Support

Keywords

  • Pharmacogenomic testing
  • Precision medicine diagnostics
  • Clinical laboratory services
  • Oncology genetic testing
  • DNA-guided prescribing

Where Mobility Health is headquartered

Location

Headquarters

HQ city
Mason
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Mobility Health business model

Business model
GTM type
B2B
Offering type
Services

Revenue model

  1. Medicare-Covered PGx Testing: Laboratory testing services for pharmacogenomic testing that is covered by Medicare, indicating reimbursement through government healthcare programs. The company provides testing services to healthcare providers who order tests for their patients.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goMedicare-covered testing for eligible patients

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Mobility Health product offering

Product offering

Core offering

Mobility Health (operating as Mira Precision Health) is a CLIA-certified clinical laboratory providing pharmacogenomic (PGx) testing services to healthcare providers. Its two flagship offerings are Mira Comprehensive PGx, covering 85+ medications across 12 therapeutic areas, and ToxNav Advantage, an oncology-focused test covering all AMP Tier 1 and Tier 2 DPYD variants plus UGT1A1 testing to assess chemotherapy toxicity risk. Tests are delivered with an industry-best 48-hour turnaround time through a secure provider portal with EMR integration.

Product overview

Mira Precision Health (Mobility Health) offers a pharmacogenomic testing platform consisting of two main branded test products: Mira Comprehensive PGx for general medication guidance across 85+ medications in 12 therapeutic areas, and ToxNav Advantage for specialized oncology pharmacogenomic testing to reduce chemotherapy toxicity. These products are supported by proprietary clinical decision support software, delivered through a provider portal, and backed by CLIA-certified in-vitro diagnostic laboratory services. All products feature a 48-hour turnaround time.

Differentiator

Problem solved

Functional benefit

Brands

  • ToxNav Advantage: Oncology pharmacogenomic testing for DPYD and UGT1A1 variants to help reduce chemotoxicity from fluoropyrimidines and irinotecan.
  • Mira Comprehensive PGx

Products and services

  • Mira Comprehensive PGx Comprehensive pharmacogenomic test providing medication guidance for 85+ commonly prescribed medications across 12 therapeutic areas including mental health, cardiology, pain management, infection/immunity, oncology, autoimmune disorders, and organ transplant care. Delivered with a 48-hour turnaround time to healthcare providers for use in clinical decision-making.
  • ToxNav Advantage Oncology-focused pharmacogenomic test covering all AMP Tier 1 and Tier 2 DPYD variants for fluoropyrimidine toxicity risk plus UGT1A1 testing for irinotecan dosing guidance. Results are aligned with FDA labeling and NCCN Clinical Practice Guidelines in Oncology. Powered by Oxford Cancer Biomarkers science, with a 48-hour turnaround time.
  • In-Vitro Diagnostics Laboratory Services CLIA-certified high-complexity clinical laboratory services specializing in advanced nucleic acid analysis, assay development and validation, and high-throughput molecular testing. Offered to laboratories, pharmaceutical partners, and clinical or R&D teams seeking custom diagnostic programs and precision-medicine initiatives.
  • Serological Testing In-vitro diagnostic services for infectious disease detection and immunity assessment, provided through the company's CLIA-certified laboratory. Targeted at healthcare providers needing serological testing support.

Quantifiable outcome

  • Industry-best 48-hour turnaround time for pharmacogenomic test results
  • +3 more outcomes

Companies that use Mobility Health

Customer profile

Named customers3 records

Segments3 records

Mobility Health technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Mobility Health partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Oxford Cancer BiomarkerscoreTechnology or IntegrationOxford Cancer Biomarkers provides the scientific foundation powering Mira Precision Health's ToxNav Advantage oncology testing platform. The partnership enables DPYD and UGT1A1 testing with results aligned to FDA labeling and NCCN Guidelines.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Mobility Health competitors and assessment

Company assessment

Broad incumbents

  • Tempus Labs: Tempus is a large precision medicine platform combining molecular profiling, data, and AI. It is a broad incumbent covering oncology molecular diagnostics and PGx-adjacent testing, competing for the same provider and oncology accounts.
  • Caris Life Sciences: Caris provides molecular profiling and AI-driven precision medicine, notably in oncology. It is a broad incumbent that overlaps with Mira's oncology pharmacogenomic and molecular diagnostic ambitions at a much larger scale.
  • GeneDx: GeneDx is an established clinical genetics and rare disease diagnostics company with broad hereditary and pharmacogenomic offerings. As a broad incumbent with national infrastructure, it competes for similar provider accounts in clinical genetic testing.
  • Castle Biosciences: Castle Biosciences is a molecular diagnostics company specializing in dermatologic and oncology tests. It is a broad incumbent in specialty molecular diagnostics, relevant as a competitor for provider-directed, oncology-related testing.
  • Myriad Genetics (Assurex Health): Myriad Genetics acquired Assurex Health to offer GeneSight, a leading mental-health PGx test. As a large, publicly traded genetics company, it is a broad incumbent that overlaps with Mira's PGx offerings but operates across a much wider diagnostic portfolio.
  • PathGroup: PathGroup is a large reference laboratory offering molecular and clinical testing across the Southeast and broader US. It is a broad incumbent in clinical laboratory services with overlapping capabilities to Mira's CLIA-certified diagnostic offerings.

Direct peers

  • OneOme: OneOme is a pharmacogenomic decision support platform offering RightMed, a multi-gene PGx test used by providers for medication guidance across similar therapeutic areas. It directly competes with Mira Comprehensive PGx in clinical pharmacology testing for healthcare providers.
  • Genomind: Genomind is a PGx testing company focused on mental health medication management, with its Genecept Assay covering psychotropic-relevant genes. It is a direct competitor in the provider-ordered PGx testing category, particularly overlapping with Mira's mental health therapeutic area.
  • RxGenomix: RxGenomix provides PGx interpretation and clinical decision support for pharmacists and providers. It directly competes in the same medication-management-PGx category as Mira Precision Health.
  • Coriell Life Sciences: Coriell Life Sciences offers pharmacogenomic testing and clinical interpretation services for healthcare organizations. It is a direct peer in PGx decision support with a similarly provider-focused go-to-market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Mobility Health social profiles

Digital presence

Mobility Health compliance and trust

Trust signal

Compliance5 records

Mobility Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mobility Health leadership team

Management profile

Number of profiles

Mobility Health funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mobility Health M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mobility Health

What does Mobility Health do?

Mobility Health (operating as Mira Precision Health) is a CLIA-certified clinical laboratory providing pharmacogenomic (PGx) testing services to healthcare providers. Its two flagship offerings are Mira Comprehensive PGx, covering 85+ medications across 12 therapeutic areas, and ToxNav Advantage, an oncology-focused test covering all AMP Tier 1 and Tier 2 DPYD variants plus UGT1A1 testing to assess chemotherapy toxicity risk. Tests are delivered with an industry-best 48-hour turnaround time through a secure provider portal with EMR integration.

Is Mobility Health a public or private company?

Mobility Health is a private company. It is classified as unknown and is currently operating.

When was Mobility Health founded?

Mobility Health was founded in 2021. It employs 11 to 50 people.

Where is Mobility Health based?

Mobility Health is headquartered in Mason, United States, in the North America region.

How does Mobility Health make money?

One revenue line is on record: medicare-Covered PGx Testing.

Who are Mobility Health's main competitors?

Broad incumbents on record are Tempus Labs, Caris Life Sciences, GeneDx, Castle Biosciences, Myriad Genetics (Assurex Health) and PathGroup. Direct peers are OneOme, Genomind, RxGenomix and Coriell Life Sciences.

Does Mobility Health have an API?

No public API is recorded for Mobility Health.

What industry is Mobility Health in?

Mobility Health's product category is Pharmacogenomic Testing Services. Its primary akta.pro industry code is HLAAANAB, Pharmacogenomics (PGx) Decision Support. Its NAICS code is 62151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals